This website is for UK Healthcare Professionals only

*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022

Resources

Downloadable materials for healthcare professionals

Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

TLS management tool


UK-VNCCLL-210461

Information on VENCLYXTO titration


UK-VNCCLL-210460
UK-VNCCLL-230046

Dosing and Administration Booklet


UK-VNCCLL-210462


Downloadable materials for your patients

Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

 

Patient guide for VEN in 1L


UK-VNCCLL-230215

Patient guide for VEN in R/R


UK-VNCCLL-230216

Patient guide for VEN in all lines 


UK-VNCCLL-230304

A guide to completing treatment with VENCLYXTO


UK-VNCCLL-230048

1L=First line; CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; R/R=relapsed/refractory; SmPC=Summary of product characteristics; VEN=VENCLYXTO. 

References

  1. VENCLYXTO Summary of Product Characteristics.
  2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
  3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on [email protected].

You are strongly advised to read the prescribing information and summary of product characteristics to evaluate patient suitability for Venclyxto.

UK-VNCCLL-230374. Date of preparation: September 2023.